‘I pumped and I pumped': What caused an Indian hospital to run out of oxygen

Baba Raghav Das Medical College Hospital in Gorakhpur, India, ran out of oxygen on Aug. 11, forcing parents to use small, hand-operated resuscitators to keep their own children breathing.

The New York Times spoke with some of the parents and physicians who were in the hospital that night. They say the hospital’s supply of liquid oxygen had been dwindling after its suppliers cut off shipments over lack of payment on a $100,000 bill. The 1,000-bed hospital had been regarded as one of the best in the area, but after 60 children died while the facility worked to restore its oxygen supply, it's now being used as an example of the country’s overburdened and poorly managed healthcare system.

The problems go beyond having too many patients. Vendors in India doing business with government officials are often squeezed for bribes and kickbacks to make sure public facilities pay them. When some parents of pediatric patients who died were ask what was to blame for oxygen running out, they simply said, “corruption.”

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.